Characteristics and outcomes of over 300,000 patients with COVID-19 and history of cancer in the United States and Spain
| Autor: | Lana Yin Hui Lai, Daniel R. Morales, Talita Duarte-Salles, Thomas Falconer, Carlos Areia, Jitendra Jonnagaddala, Kristin Kostka, Christian G. Reich, Daniel Prieto-Alhambra, Lisa M. Schilling, Dalia Dawoud, Clair Blacketer, Marc A. Suchard, Isabelle Soerjomataram, Frank J. DeFalco, George Hripcsak, Osaid Alser, Jose D. Posada, Fredrik Nyberg, Laura Hester, William Carter, Lin Zhang, Michael E. Matheny, Sergio Fernandez-Bertolin, Ying Zhang, Waheed Ul Rahman Ahmed, María Aragón, Heba Alghoul, Karthik Natarajan, Asieh Golozar, Mengchun Gong, Martina Recalde, Patrick B. Ryan, Aedín C. Culhane, Andrea Pistillo, Vignesh Subbian, Kristine E. Lynch, Thamir M. Alshammari, Albert Prats-Uribe, Yang Shen, Donna R. Rivera, Diana Puente, Anthony G. Sena, Hokyun Jeon, Karishma Shah, Elena Roel, Nigam H. Shah, Eng Hooi Tan, Paula Casajust, Scott L. DuVall, Matthew Spotniz, Anna Ostropolets, Annalisa Trama |
|---|---|
| Přispěvatelé: | Medical Informatics |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Databases Factual Outcome Assessment Epidemiology Comorbidity outcomes Medical and Health Sciences Cohort Studies Risk Factors Neoplasms Outcome Assessment Health Care Prevalence 80 and over Medicine Young adult Aetiology Child Cancer Aged 80 and over cohort Hematology Middle Aged Hospitalization Infectious Diseases Cohort oncology Female Patient Safety Cohort study Human Adult Urologic Diseases medicine.medical_specialty Adolescent Databases Young Adult Rare Diseases SDG 3 - Good Health and Well-being Clinical Research Internal medicine Influenza Human Breast Cancer Humans Adverse effect Pandemics Factual Aged Immunosuppression Therapy business.industry SARS-CoV-2 Prevention COVID-19 medicine.disease United States Influenza Health Care Good Health and Well Being El Niño Spain Observational study business 2.4 Surveillance and distribution |
| Zdroj: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol 30, iss 10 Cancer Epidemiol Biomarkers Prev. Roel, E, Pistillo, A, Recalde, M, Sena, A G, Fernández-Bertolín, S, Aragón, M, Puente, D, Ahmed, W U R, Alghoul, H, Alser, O, Alshammari, T M, Areia, C, Blacketer, C, Carter, W, Casajust, P, Culhane, A C, Dawoud, D, DeFalco, F, DuVall, S L, Falconer, T, Golozar, A, Gong, M, Hester, L, Hripcsak, G, Tan, E H, Jeon, H, Jonnagaddala, J, Lai, L Y H, Lynch, K E, Matheny, M E, Morales, D R, Natarajan, K, Nyberg, F, Ostropolets, A, Posada, J D, Prats-Uribe, A, Reich, C G, Rivera, D R, Schilling, L M, Soerjomataram, I, Shah, K, Shah, N H, Shen, Y, Spotniz, M, Subbian, V, Suchard, M A, Trama, A, Zhang, L, Zhang, Y, Ryan, P B, Prieto-Alhambra, D, Kostka, K & Duarte-Salles, T 2021, ' Characteristics and outcomes of over 300,000 patients with COVID-19 and history of cancer in the United States and Spain ', Cancer Epidemiology Biomarkers and Prevention, vol. 30, no. 10, pp. 1884-1894 . https://doi.org/10.1158/1055-9965.EPI-21-0266 Cancer Epidemiology Biomarkers and Prevention, 30(10), 1884-1894. American Association for Cancer Research Inc. |
| ISSN: | 1055-9965 |
| DOI: | 10.1158/1055-9965.epi-21-0266 |
| Popis: | Background: We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods: We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. Results: We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%–18% and 1%–14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin's lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n = 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events. Conclusions: Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. Impact: This study provides epidemiologic characteristics that can inform clinical care and etiologic studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|